Get the Stockscreener App
2.08
0.48%
0.01
After Hours:
2.11
0.03
+1.44%
Mdxhealth Sa stock is traded at $2.08, with a volume of 172.85K.
It is up +0.48% in the last 24 hours and down -28.64% over the past month.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
See More
Previous Close:
$2.07
Open:
$2.07
24h Volume:
172.85K
Relative Volume:
2.81
Market Cap:
$57.30M
Revenue:
$63.69M
Net Income/Loss:
$-44.82M
P/E Ratio:
-0.8667
EPS:
-2.4
Net Cash Flow:
$-30.56M
1W Performance:
-21.36%
1M Performance:
-28.64%
6M Performance:
-19.69%
1Y Performance:
-25.71%
1-Day Range:
$2.03
$2.165
1-Week Range:
$1.99
$2.6499
52-Week Range:
$1.99
$4.64
Mdxhealth Sa Stock (MDXH) Company Profile
Mdxhealth Sa Stock (MDXH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-23 | Initiated | TD Cowen | Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Mdxhealth Sa Stock (MDXH) Latest News
Midday Stock Roundup: STAAR Surgical CO. Shares Surge 22% - Orange County Business Journal
MDxHealth announces pricing of registered public offering - Medical Buyer
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.62% - MSN
MDXH’s Market Whiplash: -48.98% YTD Decline, -31.40% Plunge in 30 Days - The InvestChronicle
Dow Surges Over 250 Points; Accenture Earnings Top Views - Benzinga
MDXH’s price-to-book ratio: An indicator of the company’s performance - US Post News
Crude Oil Down Over 2%; US Initial Jobless Claims Fall - Benzinga
mdxHealth stock touches 52-week low at $2.0 amid market challenges - Investing.com Canada
Prostate Cancer Diagnostics Market Advancements Highlighted by Dynamics, Industry Trends, Size & Growth - WhaTech
Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket - TradingView
MDxHealth seeks $40 million through share offering - Investing.com India
MDxHealth seeks $40 million through share offering By Investing.com - Investing.com Australia
MDxHealth Announces Pricing of Offering of Ordinary Shares - 24matins.uk
MDxHealth Announces Pricing of Offering of Ordinary Shares - StockTitan
MDxHealth Announces Pricing of Offering of Ordinary Shares - EIN News
MDxHealth Shares Plunge on New Offering - Orange County Business Journal
MDxHealth seeks $40 million through share offering - Investing.com
MDxHealth seeks $40 million through share offering By Investing.com - Investing.com Canada
MDxHealth Announces Launch of Offering of Ordinary Shares - EIN News
MDxHealth (OTCMKTS:MXDHF) Trading Down 9.1% - Defense World
Cellular Health Screening Global Market Report Explores 2024 Insights, Forecast, Growth, Trends 2024-2033 - WhaTech
Liquid Biopsy Market to Reach $ 32.54 Billion, Globally, by 2033 at 11.61% CAGR: The Brainy Insights - GlobeNewswire Inc.
Q3 2024 EPS Estimates for MDxHealth SA Cut by Analyst (NASDAQ:MDXH) - Defense World
MDxHealth SA (NASDAQ:MDXH) Q2 2024 Earnings Call Transcript - Insider Monkey
MDxHealth stock supported by BTIG as Q2 revenue and guidance impress - Investing.com
Earnings call: MDxHealth posts strong Q2 results, raises 2024 guidance - Investing.com
Piper Sandler reaffirms MDxHealth stock optimism, consistent revenue outperformance - Investing.com
Piper Sandler reaffirms MDxHealth stock optimism, consistent revenue outperformance - Investing.com India
MDxHealth Q2 2024 revenues jump 32% to USD 22.2 million - Medical Buyer
MDxHealth SA (MDXH) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Raised Guidance - GuruFocus.com
MDxHealth Reports Q2 and Half Year 2024 Results - wallstreet:online
MDxHealth Reports Q2 and Half Year 2024 Results - StockTitan
MDXH (MDxHealth) EPS without NRI : $-1.49 (TTM As of Mar. 2024) - GuruFocus.com
Laboratory-Developed Tests (LDTs) World Market Forecast Report to 2028, with Coverage of the Effects of the FDA's New "Medical Devices: Laboratory Developed Tests" Rule, Passed in April 2024 - GlobeNewswire Inc.
MDxHealth (MDXH) Set to Announce Quarterly Earnings on Wednesday - Defense World
MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21 - StockTitan
Mdxhealth appoints Sanford J. Siegel to board of directors - Medical Buyer
MDxHealth shares reiterate Buy rating on raised FY'24 revenue guidance By Investing.com - Investing.com India
MDxHealth reports preliminary Q2 and half-year 2024 revenue - Medical Buyer
MDxHealth shares reiterate Buy rating on raised FY'24 revenue guidance - Investing.com
A. O. Smith sets quarterly dividend at 32 cents per share By Investing.com - Investing.com UK
MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance - StockTitan
MDxHealth (NASDAQ:MDXH) Shares Up 2.6% - Defense World
Liver Biopsy Industry Startegy Analysis} Cook Medical, Boston Scientific, Hologic, MDxHealth – Economica - Economica
Is a Surprise Coming for MDxHealth (MDXH) This Earnings Season? - Yahoo Lifestyle Singapore
MDxHealth Notice of Financial Year 2017 Results - Yahoo Lifestyle UK
MDxHealth Analytical Validation Study on AssureMDx for Bladder Cancer Published in The Journal of Urology - SelectScience
Liquid Biopsy Market Growth Developments, Strategies, Key Opportunity and Challenges Forecast to 2031 - WhaTech
Premier, Inc. (PINC) Q3 Earnings Match Estimates - Yahoo Lifestyle UK
Mdxhealth to Present at Upcoming June 2024 Investor Conferences - BioSpace
MDxHealth SA (NASDAQ:MDXH) Q1 2024 Earnings Call Transcript - Yahoo Finance
Mdxhealth Sa Stock (MDXH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
1.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):